Skip directly to content

Rare Diseases: Doing More Together



Tackling rare diseases is no easy task. Of the more than 7,000 rare diseases identified, there are treatments for only some 400; and 75 percent of those afflicted are children. That’s why a team approach is the best way to speed progress.

The Pfizer Rare Disease Consortium focuses on just this by building strong partnerships with leading academic institutions around the world. The result enables researchers to work together more effectively for patients.

As part of this approach, Pfizer’s John “Jack” Kelly, a research assistant in Pfizer’s Rare Disease Research Unit (RDRU) working on sickle cell disease, is heading to graduate studies at the University of Oxford, where he’ll work with a professor at the Structural Genomics Consortium on a project that was started in collaboration with the RDRU.

“Further cementing the power of these collaborations and how interconnected research can be, I’ll be working with Professor Wyatt Yue, who’s both an inaugural member of the Rare Disease Consortium and a long-time collaborator of another scientist in our RDRU,” Jack says. “This opportunity is a great illustration of how collaborations like these are at the frontlines in the fight against rare diseases.”